Treatment of circadian rhythm disorders
AssigneeVanda Pharmaceuticals Inc.
InventorsMarlene Michelle Dressman, John Joseph Feeney, Louis William Licamele, Mihael H. Polymeropoulos
Life of this patent
Estimating the term…
Abstract
Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.
Claims10
A method of treating a patient for a circadian rhythm disorder or for a sleep disorder wherein the patient is being treated with a strong CYP1A2 inhibitor, the method comprising:
- (A) discontinuing the CYP1A2 inhibitor treatment and then
- (B) treating the patient with tasimelteon,
- thereby avoiding the use of tasimelteon in combination with a strong CYP1A2 inhibitor.
A method of treating Non-24-Hour Sleep-Wake Disorder in a patient suffering therefrom, said method comprising internally administering to the patient an effective amount of tasimelteon.
A method of treating a patient for a circadian rhythm disorder or for a sleep disorder, the method comprising:
- (i) if the patient is being treated with a CYP3A4 inducer, then
- (A) maintaining the CYP3A4 inducer treatment and treating the patient for the circadian rhythm disorder or for the sleep disorder other than with tasimelteon or
- (B) discontinuing the CYP3A4 inducer treatment and then treating the patient with tasimelteon,
- thereby avoiding the use of tasimelteon in combination with a CYP3A4 inducer, and
- (ii) if the patient is not being treated with a CYP3A4 inducer, then treating the patient with tasimelteon, thereby avoiding the use of tasimelteon in combination with a CYP3A4 inducer.
Dependencies are inferred from the claim text.